Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis.
Ju-Li LinJian-Xian LinChao-Hui ZhengPing LiJian-Wei XieJia-Bin WangJun LuQi-Yue ChenLong-Long CaoMi LinChang-Ming HuangPublished in: BMC cancer (2020)
These findings provide further indications that postdiagnosis aspirin use improves overall survival and cancer-specific survival in colorectal cancer, especially for patients who are positive for PTGS2 (COX-2) expression and PIK3CA-mutated tumors. However, aspirin therapy does not improve overall survival in esophageal and gastric cancers, although the meta-analysis was mainly limited to retrospective studies.
Keyphrases
- low dose
- systematic review
- free survival
- end stage renal disease
- cardiovascular events
- antiplatelet therapy
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- poor prognosis
- ejection fraction
- coronary artery disease
- peritoneal dialysis
- stem cells
- case control
- case report
- cross sectional
- young adults
- acute coronary syndrome
- patient reported outcomes
- childhood cancer
- smoking cessation
- percutaneous coronary intervention
- bone marrow
- anti inflammatory drugs
- wild type